Big Law
Pfizer Strikes Three Deals to Further mRNA Technology
Pfizer Inc (PFE.N) has signed three deals to broaden the use of the messenger RNA technology (mRNA) that its COVID-19 vaccine was based on, including a pact worth as much as $1.35 billion with gene-editing specialist Beam Therapeutics (BEAM.O).
The pharmaceutical giant has been looking to advance the development of mRNA-based vaccines and therapeutics after it led global efforts develop a shot against the COVID-19 pandemic.
It said on Monday it would pay Beam $300 million upfront to do research on three new therapy targets outside the gene-editing company’s existing programs.
